Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients?: A nationwide Danish study

Carsten Lindberg Fagö-Olsen; Bent Smedegaard Ottesen; Henrik Kehlet; Sofie Antonsen; Ib Christensen; Algirdas Markauskas; Berit Jul Mosgaard; Christian Ottosen; Charlotte H Soegaard; Erik Soegaard-Andersen; Claus Hoegdall

doi:10.1016/j.ygyno.2013.11.035

Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study

Carsten Lindberg Fagö-Olsen, Bent Smedegaard Ottesen, Henrik Kehlet, Sofie Antonsen, Ib Christensen, Algirdas Markauskas, Berit Jul Mosgaard, Christian Ottosen, Charlotte H Soegaard, Erik Soegaard-Andersen, Claus Hoegdall

Research output: Contribution to journal › Journal article › Research › peer-review

53 Citations (Scopus)

Abstract

In Denmark, the proportion of women with ovarian cancer treated with neoadjuvant chemotherapy (NACT) has increased, and the use of NACT varies among center hospitals. We aimed to evaluate the impact of first-line treatment on surgical outcome and median overall survival (MOS).

Original language	English
Journal	Gynecologic Oncology
Volume	132
Issue number	2
Pages (from-to)	292-298
Number of pages	7
ISSN	0090-8258
DOIs	https://doi.org/10.1016/j.ygyno.2013.11.035
Publication status	Published - 2014

Access to Document

10.1016/j.ygyno.2013.11.035

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Fagö-Olsen, C. L., Ottesen, B. S., Kehlet, H., Antonsen, S., Christensen, I., Markauskas, A., Mosgaard, B. J., Ottosen, C., Soegaard, C. H., Soegaard-Andersen, E., & Hoegdall, C. (2014). Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecologic Oncology, 132(2), 292-298. https://doi.org/10.1016/j.ygyno.2013.11.035

@article{41506ad69d2541a584813b657d009d11,

title = "Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients?: A nationwide Danish study",

abstract = "In Denmark, the proportion of women with ovarian cancer treated with neoadjuvant chemotherapy (NACT) has increased, and the use of NACT varies among center hospitals. We aimed to evaluate the impact of first-line treatment on surgical outcome and median overall survival (MOS).",

author = "Fag{\"o}-Olsen, {Carsten Lindberg} and Ottesen, {Bent Smedegaard} and Henrik Kehlet and Sofie Antonsen and Ib Christensen and Algirdas Markauskas and Mosgaard, {Berit Jul} and Christian Ottosen and Soegaard, {Charlotte H} and Erik Soegaard-Andersen and Claus Hoegdall",

year = "2014",

doi = "10.1016/j.ygyno.2013.11.035",

language = "English",

volume = "132",

pages = "292--298",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "2",

}

Fagö-Olsen, CL, Ottesen, BS, Kehlet, H, Antonsen, S, Christensen, I, Markauskas, A, Mosgaard, BJ, Ottosen, C, Soegaard, CH, Soegaard-Andersen, E & Hoegdall, C 2014, 'Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study', Gynecologic Oncology, vol. 132, no. 2, pp. 292-298. https://doi.org/10.1016/j.ygyno.2013.11.035

TY - JOUR

T1 - Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients?

T2 - A nationwide Danish study

AU - Fagö-Olsen, Carsten Lindberg

AU - Ottesen, Bent Smedegaard

AU - Kehlet, Henrik

AU - Antonsen, Sofie

AU - Christensen, Ib

AU - Markauskas, Algirdas

AU - Mosgaard, Berit Jul

AU - Ottosen, Christian

AU - Soegaard, Charlotte H

AU - Soegaard-Andersen, Erik

AU - Hoegdall, Claus

PY - 2014

Y1 - 2014

N2 - In Denmark, the proportion of women with ovarian cancer treated with neoadjuvant chemotherapy (NACT) has increased, and the use of NACT varies among center hospitals. We aimed to evaluate the impact of first-line treatment on surgical outcome and median overall survival (MOS).

AB - In Denmark, the proportion of women with ovarian cancer treated with neoadjuvant chemotherapy (NACT) has increased, and the use of NACT varies among center hospitals. We aimed to evaluate the impact of first-line treatment on surgical outcome and median overall survival (MOS).

U2 - 10.1016/j.ygyno.2013.11.035

DO - 10.1016/j.ygyno.2013.11.035

M3 - Journal article

C2 - 24321400

SN - 0090-8258

VL - 132

SP - 292

EP - 298

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -

Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study

Abstract

Access to Document

AUB Link

Fingerprint

Cite this